LentiGlobin gene therapy for sickle cell on course for filing, says bluebirdIt has been an amazing year for patients with sickle cell disease (SCD) with two new drug approvals Share XLentiGlobin gene therapy for sickle cell on course for filing, says bluebirdhttps://pharmaphorum.com/news/lentiglobin-gene-therapy-for-sickle-cell-on-course-for-filing-says-bluebird/
FDA approves Global Blood Therapeutics’ sickle cell pillGlobal Blood Therapeutics has seen its sickle cell disease drug approved by the FDA, promising to be the Share XFDA approves Global Blood Therapeutics’ sickle cell pillhttps://pharmaphorum.com/news/fda-approves-global-blood-therapeutics-sickle-cell-pill/
CRISPR trials yield encouraging data in blood disordersData on the first two patients to be treated with a CRISPR-based drug for the blood disorders beta Share XCRISPR trials yield encouraging data in blood disordershttps://pharmaphorum.com/news/crispr-trials-yield-encouraging-data-in-blood-disorders/
GlycoMimetics craters as Pfizer says rivipansel flunks trialGlycoMimetics has been poleaxed by the news that its drug for a severe complication of sickle cell anaemia Share XGlycoMimetics craters as Pfizer says rivipansel flunks trialhttps://pharmaphorum.com/news/glycomimetics-craters-as-pfizer-says-rivipansel-flunks-trial/
Imara raises $63m for sickle cell drug trialsUS biotech Imara has raised $63 million for clinical development of its sickle cell disease drug, which is Share XImara raises $63m for sickle cell drug trialshttps://pharmaphorum.com/news/imara-raises-63m-for-sickle-cell-drug-trials/
